Linked Life Data

18371051

Source:http://linkedlifedata.com/resource/pubmed/id/18371051

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2008-11-10
pubmed:abstractText
SUMMARY: Adjuvant interferon-alpha (IFN-alpha) therapy in patients with melanoma has been established as standard therapy since more than 10 years.During IFN-alpha therapy, flu-like symptoms, gastrointestinal disorders, arthralgias and neuropsychiatric symptoms are the most common side effects. The management and prophylaxis of these side effects have been improved by a more detailed understanding of pathophysiologic mechanisms and increased clinical experience. New insights in the relevance of detection of autoantibodies and development of autoimmunity have influenced the clinical pathway substantially. This review covers the pathomechanisms, incidence and optimized therapy of IFN-alpha-associated side effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1610-0387
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
829-37, 829-38
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy.
pubmed:affiliation
Department of Dermatology, University Clinic Schleswig-Holstein, Campus Kiel, Germany. ahauschild@dermatology.uni-kiel.de
pubmed:publicationType
Journal Article, Review